Results 191 to 200 of about 1,580,994 (358)

Oncologia Moderna: Necessidade da Quebra de Paradigmas, Pré-conceitos e da Estagnação / Modern Oncology: Needs of Breaking Paradigms, Prejudice and Stagnation

, 1970
Harley Francisco de Oliveira, Gerson Hiroshi Yoshinari Júnior, Antônio César Mendes Santiago   +2 more
openalex   +2 more sources

European Undergraduate Education in Oncology: A report of the EORTC Education Branch [PDF]

, 1988
K.‐H. ROBÈRT, J. Einhorn, B. Kornhuber, Michael Peckham, R Zittoun   +4 more
openalex   +1 more source

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Journal of Clinical Oncology, 2010
P. Wen, D. R. MacDonald, D. Reardon, T. Cloughesy, A. Sorensen, E. Galanis, J. Degroot, W. Wick, M. Gilbert, A. Lassman, C. Tsien, T. Mikkelsen, Eric T. Wong, M. Chamberlain, R. Stupp, K. Lamborn, M. Vogelbaum, M. J. van den Bent, Susan M. Chang   +18 more
semanticscholar   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Physical Activity and Childhood Cancer: Present Status and Future Directions. [PDF]

Am J Lifestyle Med
Caru M, Dandekar S, Schmitz KH.
europepmc   +1 more source

Peculiarities of teaching the oncology cycle in students of foreign faculty in conditions of the COVID-19 pandemic: the department’s experience

, 1970
A. V. Prokhach, В. Ф. Завізіон, Igor Bondarenko, M.I. KHODZHUZH   +3 more
openalex   +2 more sources

A model for oncology clinical indicators [PDF]

, 1989
Robert E. Enck
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

[Retracted] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer. [PDF]

Oncol Rep
Lei Y, Guo W, Chen B, Chen L, Gong J, Li W.   +5 more
europepmc   +1 more source

Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

Molecular Oncology, EarlyView.
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza, Robert Carlsson, Coralie Gamper, Gayatri Chitale, Johan Bengzon, Gesine Paul   +5 more
wiley   +1 more source